Related Experiment Video

Updated: May 15, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Adverse events associated with mTOR inhibitors

Nicolas Pallet1, Christophe Legendre

  • 1INSERM U775, Centre Universitaire des Saints-Pères, Université Paris Descartes, 45, Rue des Saints-Pères, 75006 Paris, France. npallet@yahoo.fr

Expert Opinion on Drug Safety
|December 21, 2012
PubMed
Abstract

Insights

Mechanistic target of rapamycin (mTOR) inhibitors, including rapalogs, are crucial for cell growth regulation but cause unpredictable side effects. Identifying pathway alterations is key to managing these mTOR inhibitor toxicities.

Area of Science:

  • Pharmacology
  • Oncology
  • Cell Biology

Background:

  • The mechanistic target of rapamycin (mTOR) kinase regulates cell growth and metabolism.
  • mTOR inhibitors (mTORi), including rapalogs, are used in therapy but cause significant side effects.
  • Current mTOR inhibitors have unpredictable and potentially debilitating adverse events.

Purpose of the Study:

  • To comprehensively review the safety profiles of rapalog-based therapies.
  • To discuss potential mechanisms of mTOR inhibitor side effects.
  • To explore biological pathways regulated by mTOR in relation to safety.

Main Methods:

  • Literature review of clinical studies on rapalog-based therapies.
  • Analysis of mTOR signaling pathways and their biological roles.
  • Discussion of known mTOR inhibitor mechanisms and associated toxicities.

Main Results:

  • Rapalogs inhibit mTOR complex 1 (MTORC1) via FK-BP12 complexation.
  • ATP-competitive mTOR inhibitors target the enzyme's catalytic site.
  • Clinical data indicates frequent and severe side effects from mTORi therapies.

Conclusions:

  • Improved prevention and management of mTOR inhibitor side effects are needed.
  • Identifying alterations in related biological pathways is crucial for therapeutic targets.
  • Understanding mTOR pathway dysregulation can lead to safer mTORi development.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...